|
Symbol
|
AWSBIL | ZYALTQ | SKS4LK | OVCRCH | OZTRCH | Z0A4JZ | AANOTQ | ABVHSQ | AYSBIL | LXORLK | Z0ATYZ | CQWBKB | ACDQTQ | RMAKRV | RMAG0V | Z0B7EZ | UJERWU | LZPRCH | RMBGJV | RMBU5V |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nom | Multi Reverse Convertible | Multi Reverse Convertible | LUKB Softcallable Multi Reverse Convertible | Worst of Callable Reverse Convertible | Worst of Callable Reverse Convertible | Autocallable Reverse Convertible Defensive worst | Multi Reverse Convertible | Multi Reverse Convertible | Reverse Convertible | LUKB Multi Reverse Convertible | Autocallable Reverse Convertible Defensive worst | Reverse Convertible | Multi Reverse Convertible | Autocallable Multi Vonti | Autocallable Multi Vonti | Autocallable Reverse Convertible Defensive worst | GOAL | Worst of Callable Reverse Convertible | Multi Vonti | Multi Vonti |
|
Sous-jacent
|
Compagnie Financière Richemont SA / Logitech International SA / Sika AG / Straumann Hldg. AG | Givaudan / Sonova Hldg. AG / Straumann Hldg. AG | Julius Baer Group / Roche AG / Straumann Hldg. AG | Novartis AG / Sandoz Group AG / Straumann Hldg. AG | Kühne & Nagel Intl. AG / Straumann Hldg. AG / VAT Group | ABB / Holcim/Amrize Basket / Straumann Hldg. AG | Adecco Group AG / OC Oerlikon N / Straumann Hldg. AG / VAT Group | Sika AG / Helvetia Baloise Holding AG / Straumann Hldg. AG / Sandoz Group AG | Alcon / Sonova Hldg. AG / Straumann Hldg. AG / Ypsomed Hldg. AG | Givaudan / Julius Baer Group / Straumann Hldg. AG | Alcon / Novartis AG / Sandoz Group AG / Straumann Hldg. AG | Lonza Group N / Novartis N / Roche GS / Straumann Hldg. AG | Adecco Group AG / Logitech International SA / Stadler Rail AG / Straumann Hldg. AG / UBS Group AG | Lonza Group N / Sika AG / Straumann Hldg. AG | Lonza Group N / Sika AG / Straumann Hldg. AG | Alcon / Straumann Hldg. AG / Ypsomed Hldg. AG | Bachem Hldg. AG / Lonza Group N / Straumann Hldg. AG | SGS S.A. Ltd. / Sika AG / Straumann Hldg. AG | Alcon / Lonza Group N / Novartis AG / Straumann Hldg. AG | Lonza Group N / Novartis AG / Straumann Hldg. AG / Ypsomed Hldg. AG |
|
Emetteur
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Échéance
|
23.10.2026 | 02.11.2026 | 10.07.2026 | 09.06.2026 | 07.04.2026 | 30.03.2026 | 27.09.2029 | 07.10.2026 | 22.04.2027 | 05.03.2027 | 05.03.2027 | 13.03.2028 | 21.03.2030 | 24.06.2026 | 24.06.2026 | 10.12.2026 | 02.08.2027 | 07.08.2029 | 19.08.2027 | 22.02.2027 |
| Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Prix d'exercise
|
135,512 | 2 733,78 | 86,175 | 27,975 | 162,33 | 38,2921 | 18,304 | 183,04 | 90,86 | 2 812,194 | 96,018 | 78,705 | 74,3275 | 183,40 | 174,30 | 81,90 | 390,663 | 62,415 | 75,92 | 70,63 |
| rendement max. p.a. | 8,56% | 17,79% | 12,86% | 19,25% | 32,46% | 38,01% | 13,83% | 26,43% | 20,64% | 13,52% | 18,64% | 8,08% | 9,65% | 39,30% | 30,30% | 20,34% | 12,40% | 7,70% | 8,27% | 11,65% |
| Demande | - | 90,31 | 98,54 | - | 92,88 | - | - | 85,02 | - | - | 86,68 | 94,54 | 85,28 | 86,40 | 90,00 | 87,18 | 89,25 | - | 96,60 | 92,20 |
| Offre | - | 91,11 | 99,29 | - | 93,68 | - | - | 85,82 | - | - | 87,58 | 95,34 | 86,08 | 87,20 | 90,80 | 88,08 | 90,25 | - | 97,40 | 93,01 |